Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference